F-star Therapeutics Accounts Payable

As of the most recent data (September 2022), FSTX shows a accounts payable of $2.5M. That compares with $1.6M in the prior-year period — up 59.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FSTX's accounts payable is now $2.5M (was $1.6M) — a 59.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether F-star Therapeutics is outperforming or lagging.

Tracking FSTX's accounts payable over time shows whether F-star Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $2.5M That compares with $1.6M in the prior-year period — up 59.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has F-star Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.5M) with ownership activity and broader fundamentals.

F-star Therapeutics's accounts payable is $2.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.